One shot to stop rabies? new vaccine trial begins

NCT ID NCT04270838

Ongoing ⭐️ VACCINE ⭐️ Sponsor: University of Oxford Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new rabies vaccine called ChAdOx2 RabG, given as a single shot. It involves 174 healthy adults (18-45 years) and young children (2-6 years) in a country where rabies is common. The goal is to see if the vaccine is safe and triggers a strong immune response, comparing it to the standard multi-dose rabies vaccine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ChAdOx2 RabG (a viral-vector based rabies vaccine)
What this could lead to: If successful, this could lead to a single-dose rabies vaccine that is easier to administer than current multi-dose regimens, especially in remote areas.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 174 participants, so safety and immune response are still being evaluated. The vaccine may not provide long-lasting protection or could have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rabies prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RABIES

Contacts and locations

Locations

IHI Clinical Trial Facility

Bagamoyo, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.